New asthma inhaler shows promise in large trial
NCT ID NCT02892344
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new inhaler called QMF149, which combines two drugs (indacaterol and mometasone), against a standard steroid inhaler (mometasone alone) in 802 adults and teens with mild asthma. The goal was to see if the combination improved lung function and symptom control over 12 weeks. Results showed that QMF149 helped patients breathe better and control their asthma more effectively than the standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QMF149 (indacaterol acetate and mometasone furoate)
What this could lead to
If successful, this could offer a more effective once-daily inhaler for people with mild asthma, improving lung function and symptom control.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all asthma patients. The improvement over existing treatment may be modest, and long-term safety data are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Bulgaria, Bulgaria, Bulgaria
-
Novartis Investigative Site
Stara Zagora, Bulgaria, 6000, Bulgaria
-
Novartis Investigative Site
Pleven, 5800, Bulgaria
-
Novartis Investigative Site
Santiago, Santiago Metropolitan, 7500692, Chile
-
Novartis Investigative Site
Santiago, 8380453, Chile
-
Novartis Investigative Site
Santiago, Chile
-
Novartis Investigative Site
Viña del Mar, 2520594, Chile
-
Novartis Investigative Site
Medellín, Antioquia, 0050010, Colombia
-
Novartis Investigative Site
Bucaramanga, Colombia, Colombia
-
Novartis Investigative Site
Medellín, Colombia, Colombia
-
Novartis Investigative Site
Bogota, Cundinamarca, 110911, Colombia
-
Novartis Investigative Site
Bogotá, Colombia
-
Novartis Investigative Site
Tartu, Estonia, 51014, Estonia
-
Novartis Investigative Site
Kohtla-Järve, 30322, Estonia
-
Novartis Investigative Site
Tallinn, 13419, Estonia
-
Novartis Investigative Site
Tartu, 51014, Estonia
-
Novartis Investigative Site
Bochum, Germany, 44791, Germany
-
Novartis Investigative Site
Marburg, Germany, D-35037, Germany
-
Novartis Investigative Site
Bad Wörishofen, 86825, Germany
-
Novartis Investigative Site
Berlin, 10119, Germany
-
Novartis Investigative Site
Darmstadt, 64283, Germany
-
Novartis Investigative Site
Frankfurt, 60596, Germany
-
Novartis Investigative Site
Gauting, 82131, Germany
-
Novartis Investigative Site
Hamburg, 20354, Germany
-
Novartis Investigative Site
Hanover, 30173, Germany
-
Novartis Investigative Site
Landsberg, 86899, Germany
-
Novartis Investigative Site
Leipzig, 04207, Germany
-
Novartis Investigative Site
Lübeck, 23552, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Szarvas, Hungary, 5540, Hungary
-
Novartis Investigative Site
Szeged, Hungary, 6722, Hungary
-
Novartis Investigative Site
Győr, HUN, 9024, Hungary
-
Novartis Investigative Site
Százhalombatta, HUN, 2440, Hungary
-
Novartis Investigative Site
Törökbálint, Pest County, 2045, Hungary
-
Novartis Investigative Site
Cegléd, 2700, Hungary
-
Novartis Investigative Site
Gödöllő, 2100, Hungary
-
Novartis Investigative Site
Ahmedabad, Gujarat, 380 060, India
-
Novartis Investigative Site
Vadodara, Gujarat, 390022, India
-
Novartis Investigative Site
Bangalore, Karnataka, 560099, India
-
Novartis Investigative Site
Hubli, Karnataka, 580022, India
-
Novartis Investigative Site
Mysore, Karnataka, 570001, India
-
Novartis Investigative Site
Cherthala, Kerala, 688524, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 401107, India
-
Novartis Investigative Site
Nagpur, Maharashtra, India
-
Novartis Investigative Site
Bikaner, Rajasthan, 334003, India
-
Novartis Investigative Site
Coimbatore, Tamil Nadu, 641 045, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500018, India
-
Novartis Investigative Site
Varanasi, Uttar Pradesh, 221005, India
-
Novartis Investigative Site
Cassano delle Murge, BA, 70020, Italy
-
Novartis Investigative Site
Florence, FI, 50134, Italy
-
Novartis Investigative Site
Genova, Italy, 16147, Italy
-
Novartis Investigative Site
Fiumicino, RM, 00054, Italy
-
Novartis Investigative Site
Roma, 00161, Italy
-
Novartis Investigative Site
Chuo Ku, Tokyo, 103 0027, Japan
-
Novartis Investigative Site
Chuo-ku, Tokyo, 103-0027, Japan
-
Novartis Investigative Site
Setagaya-ku, Tokyo, 157006, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 162-0053, Japan
-
Novartis Investigative Site
Toshima-ku, Tokyo, 171-0014, Japan
-
Novartis Investigative Site
Jūrmala, LVA, LV-2015, Latvia
-
Novartis Investigative Site
Riga, LV, 1011, Latvia
-
Novartis Investigative Site
Daugavpils, LV-5417, Latvia
-
Novartis Investigative Site
Riga, LV 1002, Latvia
-
Novartis Investigative Site
Riga, LV-1001, Latvia
-
Novartis Investigative Site
Riga, LV-1004, Latvia
-
Novartis Investigative Site
Vilnius, 8109, Lithuania
-
Novartis Investigative Site
Vilnius, LT-08661, Lithuania
-
Novartis Investigative Site
Alor Star, Kedah, 05460, Malaysia
-
Novartis Investigative Site
Taiping, Perak, 34000, Malaysia
-
Novartis Investigative Site
Kuala Terengganu, Terengganu, 20400, Malaysia
-
Novartis Investigative Site
Putrajaya, 62250, Malaysia
-
Novartis Investigative Site
Santiago de Surco, Lima region, 33, Peru
-
Novartis Investigative Site
Cusco, 84, Peru
-
Novartis Investigative Site
Lima, 10, Peru
-
Novartis Investigative Site
Lima, 14, Peru
-
Novartis Investigative Site
Piura, 2000, Peru
-
Novartis Investigative Site
Iloilo City, Iloilo, 5000, Philippines
-
Novartis Investigative Site
Manila, 1008, Philippines
-
Novartis Investigative Site
Quezon City, 1100, Philippines
-
Novartis Investigative Site
Biaystok, Poland, 15-430, Poland
-
Novartis Investigative Site
Bialystok, 15-044, Poland
-
Novartis Investigative Site
Grudziądz, 86-300, Poland
-
Novartis Investigative Site
Katowice, 40 085, Poland
-
Novartis Investigative Site
Moscow, 115478, Russia
-
Novartis Investigative Site
Rostov-on-Don, 344011, Russia
-
Novartis Investigative Site
Saint Petersburg, 191015, Russia
-
Novartis Investigative Site
Saint Petersburg, 194044, Russia
-
Novartis Investigative Site
Saint Petersburg, 196240, Russia
-
Novartis Investigative Site
Yekaterinburg, 620028, Russia
-
Novartis Investigative Site
Bardejov, Slovak Republic, 085 01, Slovakia
-
Novartis Investigative Site
Bojnice, Slovak Republic, 972 01, Slovakia
-
Novartis Investigative Site
Humenné, Slovak Republic, 066 01, Slovakia
-
Novartis Investigative Site
Liptovský Hrádok, Slovak Republic, 033 01, Slovakia
-
Novartis Investigative Site
Spišská Nová Ves, Slovak Republic, 052 01, Slovakia
-
Novartis Investigative Site
Stropkov, Slovak Republic, 09101, Slovakia
-
Novartis Investigative Site
Čadca, Slovakia, 022 01, Slovakia
-
Novartis Investigative Site
Prešov, Slovakia, 080 01, Slovakia
-
Novartis Investigative Site
Zvolen, Slovakia, 960 01, Slovakia
-
Novartis Investigative Site
Banská Bystrica, SVK, 974 05, Slovakia
-
Novartis Investigative Site
Poprad, SVK, 058 01, Slovakia
-
Novartis Investigative Site
Bratislava, 841 04, Slovakia
-
Novartis Investigative Site
Sabinov, 08301, Slovakia
-
Novartis Investigative Site
Winnie Mandela, Free State, 8340, South Africa
-
Novartis Investigative Site
Middelburg, Mpumalanga, 1050, South Africa
-
Novartis Investigative Site
Belleville, South Africa, 7530, South Africa
-
Novartis Investigative Site
Cape Town, ZAF, 7570, South Africa
-
Novartis Investigative Site
Cape Town, 7531, South Africa
-
Novartis Investigative Site
Panorama, 7550, South Africa
-
Novartis Investigative Site
Anyang-si, Gyeonggi-do, 14068, South Korea
-
Novartis Investigative Site
Bucheon-si, Gyeonggi-do, 14584, South Korea
-
Novartis Investigative Site
Hwaseong-si, Gyeonggi-do, 18450, South Korea
-
Novartis Investigative Site
Suwon, Gyeonggi-do, 16499, South Korea
-
Novartis Investigative Site
Seoul, Korea, 03312, South Korea
-
Novartis Investigative Site
Seoul, Seocho gu, 06591, South Korea
-
Novartis Investigative Site
Busan, 612-896, South Korea
-
Novartis Investigative Site
Seoul, 02841, South Korea
-
Novartis Investigative Site
Stockholm, 111 57, Sweden
-
Novartis Investigative Site
Uppsala, 75237, Sweden
-
Novartis Investigative Site
Linköping, Östergötland County, 587 58, Sweden
-
Novartis Investigative Site
Bangkok, Thailand, 10400, Thailand
-
Novartis Investigative Site
Khon Kaen, THA, 40002, Thailand
-
Novartis Investigative Site
Chiang Mai, 50200, Thailand
-
Novartis Investigative Site
Ho Chi Minh City, VNM, 700000, Vietnam
-
Novartis Investigative Site
Haiphong, 180000, Vietnam